[ad_1] Single dose of RN0191 achieved up to 95% individual maximum and 87% mean maximum PCSK9 reduction, and up to 74% individual maximum and 56% mean maximal LDL-C lowering Robust and sustainable treatment effects support at […]
Tag: Pharmaceuticals
Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024
[ad_1] New preclinical results support the anti-fibrotic potential of engineered macrophages in multiple fibrosis models Engineered TIM4-expressing macrophages correct defective efferocytosis in MASH, demonstrating potent anti-fibrotic activity PHILADELPHIA, Nov. 17, 2024 /PRNewswire/ — Carisma Therapeutics Inc. (Nasdaq: […]
Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial
[ad_1] New APPEAR-C3G data show Fabhalta sustained proteinuria reduction at 12 months1 Upon Fabhalta initiation, improvement observed in estimated glomerular filtration rate (eGFR) slope – a key measure of kidney function – vs. patients’ historic […]
Icahn Enterprises L.P. Announces Q3 2024 Earnings Conference Call
[ad_1] SUNNY ISLES BEACH, Fla., Oct. 25, 2024 /PRNewswire/ — Icahn Enterprises L.P. (Nasdaq:IEP) announced today that it will discuss its third quarter 2024 results on a webcast on Friday, November 8, 2024 – 10:00 a.m. […]
RiboX Therapeutics Announces FDA Clearance for IND Application of RXRG001, the First Circular RNA Therapy for the Treatment of Radiation-Induced Xerostomia and Hyposalivation
[ad_1] PRINCETON, N.J., Oct. 25, 2024 /PRNewswire/ — RiboX Therapeutics Ltd. (RiboX), a pioneering biopharmaceutical company, focused on discovering and developing fully engineered circular RNA therapeutics, announced that the US Food and Drug Administration (FDA) has […]
